| Revenue growth | FY26 core up 27% YoY (ex-real estate); headline FY26 INR 547.8cr. |
|---|---|
| Margins | EBITDA margin held at 22.3%; optimization driving expansion. |
| Demand visibility | Positive; inventory build aligned with FY27 volume planning. |
| Management confidence | High; citing recovery continues with strong all-round financials. |
Growth
FY26 Core revenue up 27%; Vitamin D3 Human +28%; D3 Animal +32%; Green Chemistry +126% YoY.
Outlook
EBITDA margin stable at 22.3%; Debt-to-equity improved to 0.27; Free cash flow tripled to INR 62cr.
Risks
Headline PAT fell 8% YoY due to FY25 real-estate base effect; inventory build for FY27 volumes.
Earnings Call filed with BSE, NSE: FERMENTA. Summary written with AI assistance from the document.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹570.70
- Market cap
- ₹1,680 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 27.8×Sector 47.4×
- Promoter holding
- 64.09%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Other Announcement
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
- Value
- ₹0.20 Cr
Fermenta Biotech Partnership
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
- From
- Vellore Institute of Technology (VIT), Vellore
Fermenta Biotech Promoter Selling: ₹2.2 Cr
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
- Value
- ₹2.20 Cr
- Promoter stake change
- -0.15%
Fermenta Biotech Credit Rating
Fermenta Biotech Limited received a credit rating upgrade from CARE Ratings. Long-term bank facilities were raised to 'CARE BBB+; Stable' and short-term to 'CARE A2'.
- Value
- ₹173.0 Cr
Fermenta Biotech Management Change
Fermenta Biotech Limited has re-appointed Ms. Rajeshwari Datla as a Non-Executive Non-Independent Director of the company, effective August 11, 2026.
Fermenta Biotech Annual General Meeting
Fermenta Biotech held its AGM and secured shareholder approval for resolutions including financial statements, dividend declaration, and director appointments. All seven resolutions were passed successfully.